Daiichi Sankyo Initiates Pivotal Phase 3 Trial of Fam Trastuzumab Deruxtecan DS8201 in HER2 Low Metastatic Breast Cancer

Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer

08:01 EST 14 Jan 2019 | FinanzNachrichten

- DESTINY-Breast04 to evaluate [fam-] trastuzumab deruxtecan (DS-8201) versus investigator's choice in HER2 low, unresectable and/or metastatic breast cancer previously treated with standard chemo...

More From BioPortfolio on "Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer"